サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：非小細胞肺がんの世界市場：種類別・治療の種類別・薬剤クラス別・流通チャネル別・地域別の評価、機会と予測 (2016年～2030年)
市場調査レポート
商品コード
1388949

非小細胞肺がんの世界市場：種類別・治療の種類別・薬剤クラス別・流通チャネル別・地域別の評価、機会と予測 (2016年～2030年)

Non-Small Cell Lung Cancer Market Assessment, By Type, By Treatment Type, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2016-2030F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 201 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
非小細胞肺がんの世界市場：種類別・治療の種類別・薬剤クラス別・流通チャネル別・地域別の評価、機会と予測 (2016年～2030年)
出版日: 2023年12月01日
発行: Market Xcel - Markets and Data
ページ情報: 英文 201 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の非小細胞肺がん (NSCLC) の市場規模は、2022年に106億米ドルと評価され、予測期間中 (2023年～2030年) に9.5%のCAGRで成長し、2030年には219億米ドルに達すると予測されています。世界の非小細胞肺がん市場は、治療法、診断の継続的な進歩、疾患に対する理解の深まりを特徴とするダイナミックな市場です。

NSCLCは肺がんの主流であり、全肺がん症例の約85%を占めています。例えば、ACSが発表した2023年の統計によると、2023年には約238,340人の肺がん患者が新たに診断されると予想されています。この市場は、技術革新、治療戦略の進化、個別化医療に対する意識の高まりなど、さまざまな要因が複雑に絡み合って形成されています。精密医療の進歩はNSCLC治療に革命をもたらし、個々の患者に存在する特定の遺伝子変異やバイオマーカーに合わせた標的療法や免疫療法へとシフトしています。

免疫チェックポイント阻害薬や、EGFR阻害薬やALK阻害薬などの標的治療薬の登場は、従来の化学療法と比較して治療成績の改善と副作用の軽減をもたらし、治療パラダイムを大きく変革しました。さらに、新たな治療標的、革新的な併用療法、早期発見のための診断ツールの発見を目指した研究開発が進行中であり、状況は絶えず進化しています。バイオマーカー主導型治療、液体生検、コンパニオン診断薬は、治療選択において極めて重要な役割を果たし、患者に対してより正確で効果的な介入を可能にします。市場競争は激しく、製薬企業は新規治療法の導入や製品ポートフォリオの拡充のため、研究や臨床試験に多額の投資を行っています。しかし、治療費の高騰、アクセス格差、NSCLCを早期に診断するための包括的なスクリーニングプログラムの必要性など、課題は依然として残っています。

当レポートでは、世界の非小細胞肺がんの市場について分析し、製品の概略や市場の基本構造、全体的な市場規模の動向見通し、セグメント別・地域別の詳細動向、市場の背景事情や主な影響要因、主要企業のプロファイル・市場シェアなどを調査しております。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 新型コロナウイルス感染症 (COVID-19) が世界の非小細胞肺がん市場に与える影響

第4章 エグゼクティブサマリー

第5章 世界の非小細胞肺がん市場の将来展望 (2016年～2030年)

  • 市場規模と予測
    • 金額ベース
    • 数量ベース
  • 種類別
    • 扁平上皮がん
    • 大細胞がん
    • 腺がん
    • その他
  • 治療の種類別
    • 化学療法
    • 標的療法
    • 免疫療法
  • 薬剤クラス別
    • 血管新生阻害剤
    • EGFR (上皮成長因子受容体) 阻害剤
    • キナーゼ阻害剤
    • 微小管安定化剤
    • 葉酸代謝拮抗剤
    • PD-1/PD-L1阻害剤
  • 流通チャネル別
    • 病院薬局
    • ドラッグストア・小売薬局
    • オンライン薬局
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 企業別市場シェア (%、2022年)

第6章 世界の非小細胞肺がん市場の将来展望：地域別 (2016年～2030年)

  • 北米*
    • 市場規模と予測
      • 金額ベース
      • 数量ベース
    • 種類別
    • 治療の種類別
    • 薬剤クラス別
    • 流通チャネル別
    • 米国*
      • 市場規模と予測
      • 種類別
      • 治療の種類別
      • 薬剤クラス別
      • 流通チャネル別
    • カナダ
    • メキシコ

各セグメントの情報は、対象となる全ての地域・国について提供されます。

  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • 南米
    • ブラジル
    • アルゼンチン
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第7章 市場マッピング (2022年)

  • 種類別
  • 治療の種類別
  • 薬剤クラス別
  • 流通チャネル別
  • 地域別

第8章 マクロ環境と産業構造

  • 需給分析
  • 輸出入分析 (数量・金額ベース)
  • サプライ/バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第9章 市場力学

  • 成長促進要因
  • 成長抑制要因 (課題、制約)

第10章 規制の枠組みとイノベーション

  • 臨床試験
  • 特許の情勢
  • 規制当局の承認
  • イノベーション/新興技術

第11章 主要企業の情勢

  • 市場リーダー上位5社：競合マトリックス
  • 市場リーダー上位5社：市場収益分析 (%、2022年)
  • 企業合併・買収 (M&A)/合弁事業 (該当する場合)
  • SWOT分析 (市場参入企業5社の場合)
  • 特許分析 (該当する場合)

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

  • Novartis AG
    • 企業概要
    • 経営幹部
    • 製品・サービス
    • 財務状況 (報告どおり)
    • 重点市場と地理的プレゼンス
    • 最近の動向
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Merck &Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Agennix AG.

上記企業は市場シェア順ではなく、調査作業中に入手した情報に従って変更される可能性があります。

第15章 戦略提言

第16章 Market Xcelについて、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 3. Global Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 4. Global Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 5. Global Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 6. Global Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 7. Global Non-Small Cell Lung Cancer Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 8. North America Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 9. North America Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 10. North America Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 11. North America Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 12. North America Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 13. North America Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 14. North America Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 15. United States Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 16. United States Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 17. United States Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 18. United States Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 19. United States Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 20. United States Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 21. Canada Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 22. Canada Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 23. Canada Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 24. Canada Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 25. Canada Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 26. Canada Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 27. Mexico Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 28. Mexico Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 29. Mexico Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 30. Mexico Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 31. Mexico Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 32. Mexico Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 33. Europe Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 34. Europe Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 35. Europe Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 36. Europe Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 37. Europe Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 38. Europe Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 39. Europe Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 40. Germany Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 41. Germany Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 42. Germany Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 43. Germany Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 44. Germany Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 45. Germany Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 46. France Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 47. France Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 48. France Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 49. France Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 50. France Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 51. France Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 52. Italy Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 53. Italy Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 54. Italy Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 55. Italy Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 56. Italy Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 57. Italy Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 58. United Kingdom Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 59. United Kingdom Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 60. United Kingdom Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 61. United Kingdom Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 62. United Kingdom Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 63. United Kingdom Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 64. Russia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 65. Russia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 66. Russia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 67. Russia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 68. Russia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 69. Russia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 70. Netherlands Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 71. Netherlands Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 72. Netherlands Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 73. Netherlands Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 74. Netherlands Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 75. Netherlands Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 76. Spain Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 77. Spain Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 78. Spain Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 79. Spain Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 80. Spain Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 81. Spain Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 82. Turkey Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 83. Turkey Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 84. Turkey Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 85. Turkey Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 86. Turkey Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 87. Turkey Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 88. Poland Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 89. Poland Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 90. Poland Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 91. Poland Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 92. Poland Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 93. Poland Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 94. South America Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 95. South America Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 96. South America Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 97. South America Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 98. South America Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 99. South America Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 100. South America Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 101. Brazil Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 102. Brazil Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 103. Brazil Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 104. Brazil Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 105. Brazil Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 106. Brazil Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 107. Argentina Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 108. Argentina Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 109. Argentina Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 110. Argentina Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 111. Argentina Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 112. Argentina Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 113. Asia-Pacific Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 114. Asia-Pacific Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 115. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 116. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 117. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 118. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 119. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 120. India Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 121. India Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 122. India Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 123. India Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 124. India Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 125. India Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 126. China Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 127. China Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 128. China Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 129. China Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 130. China Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 131. China Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 132. Japan Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 133. Japan Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 134. Japan Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 135. Japan Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 136. Japan Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 137. Japan Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 138. Australia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 139. Australia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 140. Australia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 141. Australia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 142. Australia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 143. Australia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 144. Vietnam Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 145. Vietnam Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 146. Vietnam Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 147. Vietnam Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 148. Vietnam Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 149. Vietnam Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 150. South Korea Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 151. South Korea Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 152. South Korea Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 153. South Korea Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 154. South Korea Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 155. South Korea Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 156. Indonesia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 157. Indonesia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 158. Indonesia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 159. Indonesia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 160. Indonesia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 161. Indonesia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 162. Philippines Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 163. Philippines Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 164. Philippines Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 165. Philippines Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 166. Philippines Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 167. Philippines Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 168. Middle East & Africa Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 169. Middle East & Africa Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 170. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 171. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 172. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 173. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 174. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 175. Saudi Arabia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 176. Saudi Arabia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 177. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 178. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 179. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 180. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 181. UAE Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 182. UAE Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 183. UAE Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 184. UAE Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 185. UAE Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 186. UAE Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 187. South Africa Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 188. South Africa Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 189. South Africa Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 190. South Africa Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 191. South Africa Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 192. South Africa Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 194. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022
目次
Product Code: MX10655

Global non-small cell lung cancer market size was valued at USD 10.6 billion in 2022, and is expected to reach USD 21.9 billion in 2030, with a CAGR of 9.5% for the forecast period between 2023 and 2030F. The global non-small cell lung cancer market is a dynamic landscape characterized by ongoing advancements in treatment modalities, diagnosis, and a growing understanding of the disease.

NSCLC represents a predominant form of lung cancer, constituting approximately 85% of all lung cancer cases. For instance, according to the 2023 statistics published by ACS, about 238,340 new cases of lung cancer are expected to be diagnosed in 2023. This market is shaped by a complex interplay of factors, including technological innovations, evolving therapeutic strategies, and increasing awareness of personalized medicine. Advancements in precision medicine have revolutionized NSCLC treatment, with a shift towards targeted therapies and immunotherapies tailored to specific genetic mutations or biomarkers present in individual patients.

The emergence of immune checkpoint inhibitors and targeted therapies, such as EGFR and ALK inhibitors, has significantly transformed the treatment paradigm, offering improved outcomes and reduced side effects compared to traditional chemotherapy. Moreover, the landscape is continually evolving with ongoing research and development initiatives, aiming to discover novel therapeutic targets, innovative combination therapies, and diagnostic tools for early detection. Biomarker-driven therapies, liquid biopsies, and companion diagnostics play a pivotal role in treatment selection, enabling more precise and effective interventions for patients. Market competition is intense, with pharmaceutical companies investing significantly in research and clinical trials to introduce novel therapies and expand their product portfolios. However, challenges persist, including high treatment costs, access disparities, and the need for more comprehensive screening programs to diagnose NSCLC at earlier stages.

Strategic Partnership Between Key Players

In the dynamic landscape of the global non-small cell lung cancer market, strategic collaborations have emerged as pivotal. Major players, such as pharmaceutical firms and biotech companies, are forging impactful partnerships. Recent alliances between leading diagnostic technology providers and pharmaceutical giants aim to revolutionize treatment through precision medicine and innovative therapies. These collaborations focus on joint research, development, and commercialization, leveraging collective expertise to introduce novel treatments and diagnostic solutions.

This strategic convergence fosters a synergetic approach, propelling advancements in personalized medicine, improving patient outcomes, and reshaping the paradigm of non-small cell lung cancer management globally. For instance, Bristol Myers Squibb, finalized the acquisition of Turning Point Therapeutics on March 6, 2022. Turning Point Therapeutics is a clinical-stage precision oncology company with a lineup of internally developed investigative medications aimed at overcoming major constraints of current cancer treatments. This acquisition expanded Bristol Myers Squibb's oncology portfolio by incorporating late-stage precision oncology asset.

Technological Advancements

The global non-small cell lung cancer market has seen significant technological advancements, revolutionizing treatment approaches. Targeted therapies, such as immunotherapies and precision medicine, have reshaped the landscape. Immunotherapies like checkpoint inhibitors (PD-1/PD-L1 inhibitors) have shown remarkable efficacy in managing advanced NSCLC by enhancing the body's immune response against cancer cells. Additionally, the emergence of personalized medicine, utilizing genetic testing to identify specific mutations or biomarkers, has led to the development of drugs tailored to individual patients.

Liquid biopsies, a minimally invasive diagnostic technique, is gaining prominence for monitoring treatment response and detecting mutations. Furthermore, advancements in imaging technologies like PET scans and MRI have improved early detection and monitoring of NSCLC. In January 2023, Novocure announced the LUNAR study, which assessed the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard treatments for stage 4 non-small cell lung cancer (NSCLC) after progression following or during platinum-based therapy, successfully achieved its main objective.

New Innovations

The non-small cell lung cancer market has witnessed groundbreaking innovations aimed at revolutionizing treatment. Immunotherapies like checkpoint inhibitors, such as Pembrolizumab and Nivolumab, have reshaped the landscape by targeting specific proteins to enhance the immune response against cancer cells. Furthermore, targeted therapies like Osimertinib have shown efficacy in specific genetic mutations like EGFR, improving outcomes for patients. Liquid biopsy techniques are emerging, offering less invasive methods to detect genetic mutations, aiding in treatment decisions.

Advancements in precision medicine and biomarker testing are fostering personalized treatment approaches, optimizing therapies for individual patients. Additionally, advancements in combination therapies and innovative drug delivery systems are showing promising results in enhancing treatment efficacy and reducing side effects. During December 2022, the FDA in the United States, provided accelerated approval to Mirati's Krazati (adagrasib), offering a targeted treatment for adult patients diagnosed with KRAS-mutated locally advanced or metastatic non-small cell lung cancer.

Increasing Investment by Companies in Developing Effective Therapies

The global non-small cell lung cancer market is witnessing a significant uptick in investment by companies aimed at developing more effective therapies. This surge in investment underscores a commitment to advancing the field of oncology and addressing the unmet medical needs of patients. Companies are allocating resources to research and develop innovative treatments that encompass targeted therapies, immunotherapies, and precision medicine approaches. The increased focus is driven by a growing understanding of the molecular complexities of non-small cell lung cancer, leading to the identification of new drug targets and treatment strategies.

For example, during January 2023, DeuterOncology, a clinical-stage pharmaceutical firm, concluded a Series A financing round, securing approx. USD 6.1 million (EUR 5.65 million). This investment empowers the company to commence the phase I clinical investigation for its primary product DO-2, an enhanced MET kinase inhibitor designed as a promising targeted therapy for lung cancer, striving to be a top-tier treatment option. Recently, MET inhibitors have gained approval for treating patients with Non-Small Cell Lung Cancer (NSCLC) exhibiting the MET exon 14 skipping mutation.

Impact of COVID-19

The growth of the non-small cell lung cancer market has been significantly impacted by COVID-19. Specifically, the pandemic led to the cessation of over 200 interventional studies, as indicated by clinicaltrials.gov until July 2021, resulting in a deceleration of market expansion. Nevertheless, with the easing of restrictions and the resumption of services, there has been a renewed emphasis on conducting clinical trials for non-small cell lung cancer treatment. Notably, in October 2022, Daiichi Sankyo, Inc., in collaboration with AstraZeneca, initiated a Phase II clinical trial to assess the safety and effectiveness of trastuzumab deruxtecan in treating HER2-mutated metastatic non-small cell lung cancer (NSCLC). These endeavors are anticipated to propel market growth throughout the projected period.

Key Players Landscape and Outlook

The non-small cell lung cancer market is characterized by fragmentation and competitiveness, featuring numerous major players. These companies are implementing diverse strategic approaches like collaborations, partnerships, new product introductions, and other initiatives to maintain their standing in the market. The market features a competitive landscape with several key players driving innovation and therapeutic advancements. Immunotherapies and targeted therapies remain a focus, with ongoing clinical trials and the development of combination therapies. The market outlook is promising, with an increasing emphasis on early detection methods, liquid biopsy technologies, and the exploration of innovative drug delivery systems. Collaboration between key players, academic institutions, and biotech firms continues to drive the evolution of treatment options, underscoring a future of diversified, more effective, and personalized therapies for NSCLC patients.

In June 2022, the European Commission granted approval to Novartis's Tabrecta (capmatinib) as a standalone treatment for adults dealing with advanced non-small cell lung cancer, necessitating systemic therapy after prior treatment with immunotherapy and/or platinum-based chemotherapy.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global Non-Small Cell Lung Cancer Market

4. Executive Summary

5. Global Non-Small Cell Lung Cancer Market Outlook, 2016-2030F

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Type
    • 1.1.1. Squamous Cell Carcinoma
    • 1.1.2. Large Cell Carcinoma
    • 1.1.3. Adenocarcinoma
    • 1.1.4. Others
  • 5.3. By Treatment Type
    • 1.1.5. Chemotherapy
    • 1.1.6. Targeted Therapy
    • 1.1.7. Immunotherapy
  • 5.4. By Drug Class
    • 1.1.8. Angiogenesis Inhibitor
    • 1.1.9. Epidermal Growth Factor Receptor Blocker
    • 1.1.10. Kinase Inhibitor
    • 1.1.11. Microtubule Stabilizer
    • 1.1.12. Folate Antimetabolites
    • 1.1.13. PD-1/PD-L1 Inhibitor
  • 5.5. By Distribution Channel
    • 1.1.14. Hospital Pharmacy
    • 1.1.15. Drug Store & Retail Pharmacy
    • 1.1.16. Online Pharmacy
  • 5.6. By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. South America
    • 5.6.5. Middle East & Africa
  • 5.7. By Company Market Share (%), 2022

6. Global Non-Small Cell Lung Cancer Market Outlook, By Region, 2016-2030F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Type
      • 6.1.2.1. Squamous Cell Carcinoma
      • 6.1.2.2. Large Cell Carcinoma
      • 6.1.2.3. Adenocarcinoma
      • 6.1.2.4. Others
    • 6.1.3. By Treatment Type
      • 6.1.3.1. Chemotherapy
      • 6.1.3.2. Targeted Therapy
      • 6.1.3.3. Immunotherapy
    • 6.1.4. By Drug Class
      • 6.1.4.1. Angiogenesis Inhibitor
      • 6.1.4.2. Epidermal Growth Factor Receptor Blocker
      • 6.1.4.3. Kinase Inhibitor
      • 6.1.4.4. Microtubule Stabilizer
      • 6.1.4.5. Folate Antimetabolites
      • 6.1.4.6. PD-1/PD-L1 Inhibitor
    • 6.1.5. By Distribution Channel
      • 6.1.5.1. Hospital Pharmacy
      • 6.1.5.2. Drug Store & Retail Pharmacy
      • 6.1.5.3. Online Pharmacy
    • 6.1.6. United States*
      • 6.1.6.1. Market Size & Forecast
      • 6.1.6.1.1. By Value
      • 6.1.6.1.2. By Volume
      • 6.1.6.2. By Type
      • 6.1.6.2.1. Squamous Cell Carcinoma
      • 6.1.6.2.2. Large Cell Carcinoma
      • 6.1.6.2.3. Adenocarcinoma
      • 6.1.6.2.4. Others
      • 6.1.6.3. By Treatment Type
      • 6.1.6.3.1. Chemotherapy
      • 6.1.6.3.2. Targeted Therapy
      • 6.1.6.3.3. Immunotherapy
      • 6.1.6.4. By Drug Class
      • 6.1.6.4.1. Angiogenesis Inhibitor
      • 6.1.6.4.2. Epidermal Growth Factor Receptor Blocker
      • 6.1.6.4.3. Kinase Inhibitor
      • 6.1.6.4.4. Microtubule Stabilizer
      • 6.1.6.4.5. Folate Antimetabolites
      • 6.1.6.4.6. PD-1/PD-L1 Inhibitor
      • 6.1.6.5. By Distribution Channel
      • 6.1.6.5.1. Hospital Pharmacy
      • 6.1.6.5.2. Drug Store & Retail Pharmacy
      • 6.1.6.5.3. Online Pharmacy
    • 6.1.7. Canada
    • 6.1.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2022

  • 7.1. By Type
  • 7.2. By Treatment Type
  • 7.3. By Drug Class
  • 7.4. By Distribution Channel
  • 7.5. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Novartis AG
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. F. Hoffmann-La Roche Ltd.
  • 14.3. Bristol-Myers Squibb Company
  • 14.4. Pfizer Inc.
  • 14.5. AstraZeneca
  • 14.6. Eli Lilly and Company
  • 14.7. Merck & Co., Inc.
  • 14.8. Boehringer Ingelheim International GmbH
  • 14.9. Sanofi
  • 14.10. Astellas Pharma Inc.
  • 14.11. Takeda Pharmaceutical Company Limited
  • 14.12. Bayer AG
  • 14.13. Eli Lilly and Company
  • 14.14. GlaxoSmithKline plc.
  • 14.15. Agennix AG.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer